Deals

Rexahn Pharmaceuticals Raises Capital in CMPO/Overnight

By |

Rexahn Pharmaceuticals (RNN) announced that it has raised $6.31 million in a CMPO/Overnight transaction. The common stock was sold at $0.33 per share, an approximate 30% discount to the market price ($0.47) of RNN at deal announcement. A series of 10,521,739 60-Month Warrants with an exercise price of $0.47 per share (0.43% premium) was issued to the investors in this transaction. Burrill Merchant Advisors Group and Maxim Group acted as agents on the transaction. Placement Agent counsel was Ellenoff Grossman & Schole, and issuer counsel was Patton Boggs.

Deals

Progenics Pharmaceuticals Raises $22M in CMPO/Overnight

By |

Progenics Pharmaceuticals (PGNX) announced that it has raised $22 million in a CMPO/Overnight transaction. The common stock was sold at $2.00 per share, an approximate 5% discount to the market price ($2.11) of PGNX at deal announcement. Jefferies & Co. acted as the exclusive agent on the transaction. Placement Agent counsel was Wilmer Cutler Pickering Hale & Dorr, and issuer counsel was O'Melveny & Myers. The transaction is expected to close by Dec.

Deals

BioDelivery Sciences Raises $40M in Double RDO

By |

BioDelivery Sciences International (BDSI) announced that it has raised $28.6 million in a Registered Direct common stock transaction and $11.4 million in a Registered Direct Convertible Preferred Stock transaction. The common stock was sold at $4.21 per share, an approximate 0.47% discount to the market price ($4.23) of BDSI at deal announcement. The fixed conversion price of the Convertible Preferred Stock is $4.21 per share, an approximate 0.47% discount to the market price at deal announcement. William Blair acted as lead agent with JMP Securities and Roth Capital Partners acting as co-agents. Brinson Patrick Securities and Ladenburg Thalmann acted as financial advisors on the transaction. Placement Agent counsel was Latham & Watkins, and issuer counsel was Ellenoff Grossman & Schole.

Deals

Aegis Capital Placing Echo Therapeutics CMPO/Overnight

By |

Echo Therapeutics (ECTE)  is in the process of raising capital via a CMPO/Overnight offering. The company is developing technologies for needle-free administration of medications. Deal Information from Placement Tracker:

A preliminary prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Electronic copies of the preliminary prospectus supplement, when available, and accompanying base prospectus may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com.